Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Vitamins C & E (Antioxidants)

The Preeclampsia Hypothesis That Failed

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

9 human trials, about 12 studies, Meta-analysis: 9 trials, 19,810 women. The written rationale for this grade is still being prepared.

FDA
Essential vitamins at normal intake; high-dose antioxidant use for preeclampsia not supported
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

The risk is the whole point of this entry. High-dose vitamin C (1,000 mg) and E (400 IU) taken to try to prevent pre-eclampsia did not work in any of the large trials, and they were associated with real harms: more low-birth-weight infants in the VIP trial (RR 1.15), and more gestational hypertension (RR 1.11) and premature rupture of membranes (RR 1.73) in the meta-analysis of 19,810 women. There is no justification for deliberate high-dose antioxidant supplementation for this purpose in pregnancy. Normal dietary intake of these vitamins and the modest amounts in a standard prenatal are a separate matter and are not the concern. Any decision about supplements, doses, or pre-eclampsia prevention in pregnancy should be made with your obstetric provider, who can weigh your individual risk and the interventions that do have evidence behind them.

Vitamins C and E are essential nutrients, and at normal dietary intake or the modest amounts in a standard prenatal they are not the subject here. This entry is about a specific high-dose use: the once-promising idea that antioxidant megadoses could prevent pre-eclampsia. Oxidative stress looked like a driver of the disease, early studies were encouraging, and the hypothesis was elegant. Then it was tested properly. Large randomized trials on three continents, and a meta-analysis of 9 trials and 19,810 women, found pre-eclampsia rates that were identical in the supplement and placebo groups. Some trials found the supplemented women had more low-birth-weight babies, more gestational hypertension, and more premature rupture of membranes. The settled conclusion across the literature is that high-dose vitamin C and E supplementation to prevent pre-eclampsia is not justified in pregnancy.

A compelling theory, that antioxidants prevent preeclampsia, that large trials tested thoroughly and found not only useless but, at high doses, possibly harmful.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Meeting ordinary vitamin C and E needs through food, which is not the issue in this entry
  • Understanding why a biologically plausible hypothesis can still fail in rigorous trials
  • Recognizing that high-dose antioxidant supplementation is not recommended for pre-eclampsia prevention
  • Seeing why large randomized trials, not mechanism or early markers, decide questions like this

What people get wrong

  • Often saidAntioxidant vitamins like C and E help prevent pre-eclampsia.

    ActuallyThey do not. The antioxidant-prevention hypothesis was tested in several large randomized trials and a meta-analysis of 19,810 women (Conde-Agudelo, AJOG 2011), which found the exact same pre-eclampsia rate in both groups, 9.6% versus 9.6% (RR 1.00). The Cochrane review reached the same conclusion.

  • Often saidIf a supplement is a natural antioxidant, then more must be protective.

    ActuallyHigh-dose vitamins C and E are natural antioxidants, and in these trials they were not only useless against pre-eclampsia but associated with more low-birth-weight babies in the VIP trial (RR 1.15) and more gestational hypertension and premature rupture of membranes in the pooled analysis. 'Natural antioxidant' is not a promise that a megadose is safe or helpful.

  • Often saidA strong biological mechanism is enough reason to take a supplement in pregnancy.

    ActuallyThe oxidative-stress mechanism was genuinely plausible and had early marker data behind it, and it still failed when tested in tens of thousands of women. Mechanism and marketing are not the same as an outcome that holds up in randomized trials, which is why any pregnancy supplement plan belongs with your obstetric provider rather than a label claim.

Who profits, and who pushes back

  • VIP trial investigators

    opposesRCT in women at risk

    Concomitant supplementation with vitamin C and vitamin E does not prevent preeclampsia in women at risk but does increase the rate of low-birthweight babies; use of these high-dose antioxidants is not justified in pregnancy.

  • Meta-analysis (9 trials, ~19,810 women)

    opposesSystematic review

    There were no significant differences in preeclampsia between vitamin and placebo groups (9.6% vs 9.6%); supplementation with vitamins C and E during pregnancy does not prevent preeclampsia.

  • NEJM and DAPIT trial teams

    cautionsUS and type-1-diabetes RCTs

    Daily 1,000 mg vitamin C and 400 IU vitamin E did not reduce preeclampsia or serious perinatal outcomes; the evidence built steadily against routine antioxidant use.

  • Baseline-deficiency caveat

    mixedResidual open question

    A narrow open question remains about whether women with genuinely low antioxidant status at baseline might respond differently, but this does not support general high-dose use.

Where the research comes from

Most of the published research on this comes from one place. 100% of it is from Trials showing no benefit. Findings that no unrelated group has reproduced are weaker than the study count makes them look.

Share of published research by country of origin.
PlaceShare of published research
Trials showing no benefit100%

Research published from: Global.

How we got here

Interest in antioxidants and pre-eclampsia grew from work in the 1990s, when researchers in the United Kingdom and elsewhere proposed that oxidative stress at the placenta helped drive the disease. A small trial led by Lucilla Poston's group in London (Chappell 1999) reported that vitamins C and E lowered a marker of pre-eclampsia in high-risk women, and the finding drew wide attention. Through the 2000s the hypothesis was put to larger tests: the VIP trial across UK hospitals, an Australian and United States trial reported in the New England Journal of Medicine, an International trial (INTAPP) run partly in Latin America, and a World Health Organization multicentre trial deliberately sited in lower-income countries with poorer baseline nutrition, where any benefit should have been easiest to see. None showed prevention, and several showed harm. By 2011 the pooled analyses were conclusive, and the idea moved from promising lead to textbook example of a mechanism that did not translate.

  1. 1990sOxidative-stress models of pre-eclampsia make placental antioxidants a plausible target
  2. 1999Chappell pilot trial (Lancet) reports a favorable marker signal in high-risk women, driving enthusiasm
  3. 2006VIP trial (Lancet) and the Rumbold ACT trial (NEJM): no prevention; both note more low-birth-weight babies
  4. 2008Cochrane review (Rumbold): 10 trials, 6,533 women, no reduction in pre-eclampsia
  5. 2009WHO multicentre trial (BJOG) in low-nutrition settings finds no effect, RR 1.0
  6. 2010DAPIT (Lancet) shows no benefit even in women with type 1 diabetes, a very high-risk group
  7. 2011Conde-Agudelo meta-analysis (AJOG), 9 trials and 19,810 women: RR 1.00, plus more gestational hypertension and PROM

At a glance

Doses tested
1,000 mg C + 400 IU E
Preeclampsia effect
None (RR 1.00)
Harm signal
More low-birth-weight, gest. HTN
Verdict
Not justified in pregnancy

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Vitamins C & E (Antioxidants). A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources